CCM
NGNE icon

Coldstream Capital Management’s Neurogene NGNE Stock Holding History

Coldstream Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20
Closed -$235 – 2524
2025
Q1 		$235 Buy
+20
New +$347 ﹤0.01% 3470

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Coldstream Capital Management's NGNE Position: Q2 2025 in Review

Coldstream Capital Management sold out of Neurogene (NGNE) in Q2 2025, closing a stake of 20 shares — an estimated $235 sold.

Coldstream Capital Management first reported a position in NGNE in Q1 2025 and held it in 1 quarter. The position peaked at $235 in Q1 2025. 82 funds tracked by Wall St. Rank hold NGNE as of Q2 2025.

  • Coldstream Capital Management reported no remaining Neurogene position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 20 Neurogene shares in Q2 2025, an estimated $235.
  • Coldstream Capital Management first reported a position in Neurogene in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Neurogene position peaked at $235 in Q1 2025.
  • 82 funds tracked by Wall St. Rank held Neurogene as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.